Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.

Launched by MASSACHUSETTS GENERAL HOSPITAL · May 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of the HPV vaccine in preventing infections among women who are living with HIV. Specifically, it looks at whether giving a single dose of the nonavalent HPV vaccine right away, or delaying it, is more beneficial for participants who have already received one dose of the HPV vaccine before they were diagnosed with HIV. The trial aims to help improve health outcomes for women who are at risk of HPV-related diseases.

To be eligible for the study, participants must be assigned female at birth, at least 16 years old, and currently living with HIV. They should have received one dose of the HPV vaccine prior to their HIV diagnosis and must be sexually active in the last six months. Participants should not have certain health conditions or be enrolled in other specific medical studies. Those who join the trial will receive either the vaccine immediately or after a delay and will be asked to provide updates about their contact information throughout the study. This research could help pave the way for better prevention methods for women with HIV.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Assigned female at birth
• • 2. Age 16 years and above on the day of signing the informed consent form
• • 3. Living with HIV with confirmed test results or clinic records
• • 4. History of receiving a single dose of an HPV vaccine before HIV diagnosis
• • 5. Self-reported sexually active in the last six months
• • 6. Lives within the study area and willing to provide updated locator information over the course of the study
• • 7. Does not have an autoimmune, degenerative, or genetic disease
• • 8. Does not have known advanced HIV (as per stage IV World Health Organization clinical staging criteria for HIV)
• • 9. No other Investigator-determined factor would limit participation in the trial
• • 10. Has not and is not enrolled in a monoclonal, investigational vaccine, or a large quantity blood draw study
• • 11. The participant has a cervix
• Exclusion Criteria:
• • 1. Anyone with cervical abnormality on examination
• • 2. Anyone with an allergy to vaccine components or yeast

Trial Officials